Sanofi: Dermatitis, Atopic trials

The registry lists 43 Dermatitis, Atopic studies with Sanofi as lead sponsor. 5 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 10Phase 3 10Phase 4 8No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationNot yet recruitingNCT07919899Phase 3
• A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisNot yet recruitingNCT07905547Phase 4
• The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisRecruitingNCT07467564
• This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic TreatmentRecruitingNCT07290803
• A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab TreatmentRecruitingNCT06192563
• Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisTerminatedNCT06058156Phase 2Results posted
• Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD StudyCompletedNCT05131477Phase 2Results posted
• Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisCompletedNCT05018806Phase 2Results posted
• Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic DermatitisCompletedNCT04992546Phase 2Results posted
• Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic DermatitisCompletedNCT04823130Phase 4Results posted
• Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic DermatitisCompletedNCT04718870Phase 4Results posted
• Dupilumab Skin Barrier Function Study in Atopic DermatitisCompletedNCT04447417Phase 4Results posted
• SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"CompletedNCT04033367Phase 4Results posted
• Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic DermatitisCompletedNCT03912259Phase 3Results posted
• French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)Active, not recruitingNCT06837454
• A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisCompletedNCT06790121Phase 2
• An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 SubstratesCompletedNCT06686628Phase 1
• Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in SpainActive, not recruitingNCT06415175
• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisActive, not recruitingNCT06407934Phase 3
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorActive, not recruitingNCT06241118Phase 3
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsCompletedNCT06224348Phase 3
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)CompletedNCT06181435Phase 3
• A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving DupilumabActive, not recruitingNCT06169527
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisCompletedNCT06130566Phase 3
• Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic DermatitisCompletedNCT06099704
• Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic DermatitisActive, not recruitingNCT06039241
• A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboCompletedNCT06015308Phase 2
• A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic DermatitisActive, not recruitingNCT05983068Phase 4
• Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic DermatitisActive, not recruitingNCT05769777Phase 2
• Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in ChinaCompletedNCT05680298Phase 4
• Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in ChinaCompletedNCT05624112Phase 4
• A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech RepublicCompletedNCT05527964
• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsActive, not recruitingNCT05492578Phase 2/3
• A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in TaiwanCompletedNCT05442645
• A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)CompletedNCT05235724
• A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf CountriesCompletedNCT05214326
• Dupilumab in Japanese Patients With Atopic DermatitisCompletedNCT04678882Phase 3
• Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)Active, not recruitingNCT03992417
• Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)CompletedNCT03849716
• A Study of KY1005 in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03754309Phase 2
• Observational Evaluation of Atopic Dermatitis in Pediatric PatientsActive, not recruitingNCT03687359
• Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)CompletedNCT01244230Phase 2/3
• Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)WithdrawnNCT00389103Phase 1